{
    "doi": "https://doi.org/10.1182/blood.V114.22.2776.2776",
    "article_title": "Varying Importance of Prognostic Factors in Subgroups of Myelodysplastic Syndromes Defined by Blast Count, Cytogenetic Risk Group, or WHO Classification. ",
    "article_date": "November 20, 2009",
    "session_type": "Myelodysplastic Syndromes Poster II",
    "abstract_text": "Abstract 2776 Poster Board II-752 Introduction: We wondered whether prognostic factors have similar relevance in different subpopulations of MDS patients. Methods: Our analysis was based on patients with primary, untreated MDS, including 181 RA, 169 RARS, 649 RCMD, 322 RSCMD, 79 5q-syndromes, 290 RAEB I, 324 RAEB II, 266 CMML I, 64 CMML II, and 209 RAEB-T. The impact of prognostic variables in univariate analysis was compared in subpopulations of patients defined by medullary blast count, namely <5%, \u22655% ( table ), \u226510%, and \u226520% (not shown), as well as 3 subpopulations defined by the cytogenetic risk groups according to IPSS ( table ). Multivariate analysis of prognostic factors was performed for cytogenetically defined subgroups and WHO-subtypes.  / . <5% blasts . \u22655% blasts . Cytogenetic risk group . good . intermediate . poor . Log-Rank . p . Log-Rank . p . / . Log-Rank . p . Log-Rank . p . Log-Rank . p . Hemoglobin </\u226510g/dl  76 <0,0001 90 <0,0001 / 24,1 <0,0001 0,74 0,38 2,6 0,1 Sex m/w  14 0,0002 0,4 0,52 / 31 <0,0001 3 0,08 0 0,9 Age </\u226560years  64 <0,0001 10,5 0,001 / 42 <0,0001 4,1 0,04 1 0,3 LDH </\u2265200U/l  55 <0,0001 33 <0,0001 / 30 <0,0001 10,2 0,001 4 0,04 Platelets </\u226550000/\u03bcl  29 <0,0001 35 <0,0001 / 4,8 0,027 6,8 0,0091 13 0,0003 ANC </\u22651000/\u03bcl  4 0,04 3 0,08 / 0,8 0,8 0,8 0,37 2,9 0,08 WBC </\u226520000/\u03bcl  21 <0,0001 3,8 0,051 / 17,9 <0,0001 15,2 0,0001 4,4 0,03 Transfusion y/n  72 <0,0001 68 <0,0001 / 11,7 0,0006 0,3 0,5 3 0,08 Fibrosis y/n  10 0,001 10,2 0,001 / 4,9 0,02 1,5 0,2 0,4 0,5 Karyotype-risk  51 <0,0001 45 <0,0001 / / / / / / / Blast count </\u2265 5%  / / / / / 36,6 <0,0001 9,8 0,001 8,9 0,02 Blast count </\u2265 10%  / / / / / 54,7 <0,0001 6,2 0,01 12,4 0,0004 Blast count </\u2265 20%  / / / / / 58,4 <0,0001 3,1 0,08 9 0,0026 / . <5% blasts . \u22655% blasts . Cytogenetic risk group . good . intermediate . poor . Log-Rank . p . Log-Rank . p . / . Log-Rank . p . Log-Rank . p . Log-Rank . p . Hemoglobin </\u226510g/dl  76 <0,0001 90 <0,0001 / 24,1 <0,0001 0,74 0,38 2,6 0,1 Sex m/w  14 0,0002 0,4 0,52 / 31 <0,0001 3 0,08 0 0,9 Age </\u226560years  64 <0,0001 10,5 0,001 / 42 <0,0001 4,1 0,04 1 0,3 LDH </\u2265200U/l  55 <0,0001 33 <0,0001 / 30 <0,0001 10,2 0,001 4 0,04 Platelets </\u226550000/\u03bcl  29 <0,0001 35 <0,0001 / 4,8 0,027 6,8 0,0091 13 0,0003 ANC </\u22651000/\u03bcl  4 0,04 3 0,08 / 0,8 0,8 0,8 0,37 2,9 0,08 WBC </\u226520000/\u03bcl  21 <0,0001 3,8 0,051 / 17,9 <0,0001 15,2 0,0001 4,4 0,03 Transfusion y/n  72 <0,0001 68 <0,0001 / 11,7 0,0006 0,3 0,5 3 0,08 Fibrosis y/n  10 0,001 10,2 0,001 / 4,9 0,02 1,5 0,2 0,4 0,5 Karyotype-risk  51 <0,0001 45 <0,0001 / / / / / / / Blast count </\u2265 5%  / / / / / 36,6 <0,0001 9,8 0,001 8,9 0,02 Blast count </\u2265 10%  / / / / / 54,7 <0,0001 6,2 0,01 12,4 0,0004 Blast count </\u2265 20%  / / / / / 58,4 <0,0001 3,1 0,08 9 0,0026 View Large Results: Strong prognostic factors in all blast-defined subgroups were hemoglobin, transfusion dependency, increased WBC, age, and LDH. However, all variables became less important in patients with \u226520% blasts (RAEB-T) and increased WBC was rare. Platelet count and cytogenetic risk groups were relevant in patients with <5%, \u22655%, and \u226510% marrow blasts, but not in RAEB-T. Marrow fibrosis was important in patients with <5% or \u22655% blasts, but not \u226510%. Gender and ANC <1000/\u03bcl were significant only in patients with a normal blast count. Furthermore, we looked for the effect of the karyotypes, relevant for IPSS scoring (-Y, del5q, del20q, others, del7q/-7, complex), and found a comparable influence on survival, irrespective whether patients had < or \u22655% marrow blasts. In subpopulations defined by cytogenetic risk groups, several prognostic factors were highly significant in univariate analysis, if patients had a good risk karyotype. These included hemoglobin, sex, age, LDH, increased WBC, transfusion need, and blast count (cut-offs 5%, 10%, and 20%). In the intermediate risk group only LDH, platelets, WBC, and blasts were significant prognostic factors, while in the high risk group only platelets and blast count remained significant. Multivariate analysis was performed for the cytogenetic risk groups and for subgroups defined by WHO subtypes. The analysis considered blast count (</\u22655%), hemoglobin, platelets, ANC, cytogenetic risk group, transfusion need, sex, and age. In the subgroup including RA, RARS, and 5q-syndrome, LDH, transfusion, and age in descending order were independent prognostic parameters. In the RCMD+RSCMD group, karyotype, age, transfusion, and platelets were relevant factors. In the RAEB I+II subgroup, the order was hemoglobin, karyotype, age, and platelets, while in CMML I+II only hemoglobin had independent influence. In RAEB-T none of the factors examined was of independent significance. Looking at cytogenetic risk groups, in the favorable group, several variables independently influenced survival, namely transfusion, blasts, age, sex, and LDH (in this order). Interestingly, in the intermediate and high risk group, only blast count and platelets retained a significant impact. Conclusion: Univariate analysis showed prognostic factors (except ANC) included in IPSS and WPSS are relevant in most subgroups defined by marrow blast percentage. However, they all lose their impact if the blast count exceeds 20%. Regarding cytogenetic risk groups, several prognostic factors lose their influence already in the intermediate risk group. This underscores the prognostic importance of MDS cytogenetics. Multivariate analysis showed MDS subpopulations defined by WHO types also differ with regard to prognostic factors. In particular, CMML and RAEB-T stand out against the other MDS types. Disclosures: Kuendgen: Celgene: Honoraria. Hildebrandt: Celgene: Research Funding. Gattermann: Novartis: Honoraria, Participation in Advisory Boards on deferasirox clinical trials. Germing: Novartis, Celgene: Honoraria, Research Funding.",
    "topics": [
        "basic local alignment search tool",
        "cytogenetics",
        "myelodysplastic syndrome",
        "prognostic factors",
        "world health organization",
        "refractory anemia with excess blasts",
        "hemoglobin",
        "transfusion",
        "karyotype determination procedure",
        "leukemia, myelomonocytic, chronic"
    ],
    "author_names": [
        "Andrea Kuendgen",
        "Corinna Strupp",
        "Kathrin Nachtkamp",
        "Barbara Hildebrandt",
        "Rainer Haas",
        "Norbert Gattermann",
        "Ulrich Germing"
    ],
    "author_dict_list": [
        {
            "author_name": "Andrea Kuendgen",
            "author_affiliations": [
                "Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine University, Duesseldorf, Germany, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Corinna Strupp",
            "author_affiliations": [
                "Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Kathrin Nachtkamp",
            "author_affiliations": [
                "Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Barbara Hildebrandt",
            "author_affiliations": [
                "Human Genetics, University of Du\u0308sseldorf, Du\u0308sseldorf, Germany"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rainer Haas",
            "author_affiliations": [
                "Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine University, Duesseldorf, Germany, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Norbert Gattermann",
            "author_affiliations": [
                "Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ulrich Germing",
            "author_affiliations": [
                "Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-13T18:46:19",
    "is_scraped": "1"
}